{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/alopecia-androgenetic-female/diagnosis/investigations/","result":{"pageContext":{"chapter":{"id":"5c4491cc-a38e-5798-9ea5-303e2514c88a","slug":"investigations","fullItemName":"Investigations","depth":2,"htmlHeader":"<!-- begin field 35d4313f-6609-4aa9-911a-8a093f63acca --><h2>What investigations should I consider?</h2><!-- end field 35d4313f-6609-4aa9-911a-8a093f63acca -->","summary":"","htmlStringContent":"<!-- begin item fb6e2542-e597-4a08-a9bc-3b7f2e4e5bbb --><!-- begin field 2eca1e6d-2a99-47c0-9a3d-0f61924799b8 --><ul><li><strong>Laboratory testing for the diagnosis of androgenetic alopecia is generally unnecessary, </strong>as the diagnosis is usually made on the woman's history and clinical findings alone.</li><li><strong>Consider checking thyroid function, full blood count, and ferritin level, </strong>particularly if <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/diagnosis/differential-diagnosis/\">telogen effluvium</a> is suspected, the presentation is atypical, or there are features that suggest hypothyroidism or anaemia.<ul><li>See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a>, <a class=\"topic-reference external-reference\" href=\"/topics/anaemia-iron-deficiency/\">Anaemia - iron deficiency</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/anaemia-b12-folate-deficiency/\">Anaemia - B12 and folate deficiency</a> for more information.</li></ul></li><li><strong>Consider basic endocrine investigations if there are features of <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/diagnosis/diagnosis-assessment/#androgen-excess\">androgen excess</a>. </strong><ul><li>Initial tests may include:<ul><li>Free-androgen index — combined hormonal contraception should be stopped 2 months before measuring this. The test should be taken early in the morning, ideally between the second and fifth day of the menstrual cycle. See the section on <em>Diagnostic investigations</em> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/polycystic-ovary-syndrome/\">Polycystic ovary syndrome</a> for further information.</li><li>Prolactin level.</li></ul></li><li>If levels are abnormal or there is any uncertainty, seek specialist advice or refer to an endocrinologist depending on clinical judgement.</li></ul></li></ul><!-- end field 2eca1e6d-2a99-47c0-9a3d-0f61924799b8 --><!-- end item fb6e2542-e597-4a08-a9bc-3b7f2e4e5bbb -->","topic":{"id":"34cafa57-9383-5d80-b924-585fddfaf630","topicId":"ee168cae-489c-42c8-b09e-953c3911c90a","topicName":"Alopecia, androgenetic - female","slug":"alopecia-androgenetic-female","lastRevised":"Last revised in May 2016","chapters":[{"id":"ed7eb17b-bb56-55c8-93ed-c69fffb8ffb2","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"50eed0df-a1f0-5171-9181-43ae31f74c24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a335b9ba-ae97-56fc-8f3c-67269d2cebee","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"423c1f05-2850-5fc3-9dfe-32260c543c30","slug":"changes","fullItemName":"Changes"},{"id":"98782d6b-86e0-52c6-874d-d38c3a7b8b43","slug":"update","fullItemName":"Update"}]},{"id":"c3b76113-c0a5-51d2-9626-e50262eb0b51","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"26174a6e-62fc-5925-bdc7-6dec1e3cc672","slug":"goals","fullItemName":"Goals"},{"id":"268ede25-aeb2-59d0-8650-e83fb2b7237c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0de2e8e-6151-5970-b442-dab292556f28","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"beac34dd-51e9-51be-b40d-b68c2f22bab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7238b814-3ad5-52e6-ad73-5c5e25e26035","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16239c30-d709-5fbe-b215-e9181602c63f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3e8ded1e-bf8c-5ab8-bae3-0a3718045265","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2a41bf35-6b01-5146-9673-3480759cf2b2","slug":"definition","fullItemName":"Definition"},{"id":"3f9115db-2801-58d5-8b38-614632cc8518","slug":"causes","fullItemName":"Causes"},{"id":"22dc1f21-64e2-59d3-9248-27696a2ff2f3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d994014c-2572-5645-8d46-23c950e5e12f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b2055ae4-a6c4-5ea6-8abb-2ada0bfe997f","slug":"complications","fullItemName":"Complications"},{"id":"f6b263b5-2a9d-5889-b83a-31313b2349ba","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c98a08a0-1460-5525-b53e-e7dd062f5271","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d05f7dc4-15b4-51a7-9040-1f13534d2bcd","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"5c4491cc-a38e-5798-9ea5-303e2514c88a","slug":"investigations","fullItemName":"Investigations"},{"id":"8ec69667-1bf4-5d04-8c65-48f0cca236b3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dcc3e89f-77d3-55b8-96a0-7f18236d81ed","fullItemName":"Management","slug":"management","subChapters":[{"id":"84a05021-8d2e-500f-bac8-1152758fd81c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d947b9be-2aca-5db0-bde3-bd1288f9fe15","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52c6980c-f25c-5733-a13e-000bf03bd936","slug":"topical-minoxidil-2percent-solution","fullItemName":"Topical minoxidil 2% solution"}]},{"id":"1f4c5c98-e1a3-5353-af89-7c80d4173e69","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a13caaee-1053-53e3-9663-af5cdb6967c3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c996db3c-f9be-5ca7-8fbf-6d8cc2a1dccf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"66cae4ab-b2ad-5800-b305-3061debc9954","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4f39a0f4-1a5f-51fa-ad3f-0bc3472e20ae","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebbfb681-3de5-545e-9479-c10e9c16eac3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb1f7555-0114-5914-8728-1ba58437da39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2ef85d5b-cf19-51e6-b768-e1dfbdc625a0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c98a08a0-1460-5525-b53e-e7dd062f5271","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"c7b5bcb6-9e4d-559d-b148-b2d362c8b4f3","slug":"basis-for-recommendation-81a","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 8ec4485c-9e7a-4f0a-939a-7db65d5f0f9e --><h3>Basis for recommendation</h3><!-- end field 8ec4485c-9e7a-4f0a-939a-7db65d5f0f9e -->","summary":null,"htmlStringContent":"<!-- begin item 81af5581-5a95-4e4f-9732-8f56d4f31a3b --><!-- begin field a1af8d59-cdd0-47ea-b75e-46ee5c308da6 --><p>The recommendations on laboratory investigations are based on a European consensus guideline for the diagnostic evaluation of androgenetic alopecia in men, women, and adolescents [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Blume-Peytavi et al, 2010</a>], expert opinion in review articles for the diagnosis and management of androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Herskovitz et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Levy and Emer, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Torres et al, 2015</a>], and a British Medical Journal Best Practice article for androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">BMJ, 2015</a>].</p><h4><strong>Checking thyroid function and ferritin levels</strong></h4><ul><li>Iron deficiency and hypothyroidism are both associated with telogen effluvium, which may coexist with androgenetic alopecia. There is uncertainty regarding the role of iron deficiency specifically in androgenetic alopecia, and routine testing is not recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Blume-Peytavi et al, 2010</a>].</li></ul><h4>Considering endocrine investigations</h4><ul><li>This recommendation is based on expert consensus that an extensive endocrinological workup is not necessary in most women with androgenetic alopecia, but that basic endocrine investigations should be carried out if the woman has features suggestive of androgen excess [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Blume-Peytavi et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Herskovitz et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Levy and Emer, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">BMJ, 2015</a>]. Recommended tests are measurement of the free-androgen index (FAI) and prolactin level. However, previous expert reviewers of this CKS topic differed on their opinion of the initial endocrine testing to perform when hyperandrogenism is suspected.<ul><li><strong>Free-androgen index (FAI)</strong><ul><li>Androgen status can be assessed by calculating the FAI, which requires measurement of total testosterone and sex-hormone binding globulin (SHBG).</li><li>Testosterone is almost entirely bound to transport proteins in the blood, mainly SHBG and albumin. Only free testosterone is biologically active, and its concentration is strongly influenced by the level of SHBG.</li><li>The FAI equals the total testosterone level (in nanomol/L x 100) divided by the SHBG level (in nanomol/L). The normal value for FAI is less than 5. Levels above this indicate androgen excess, as can occur in conditions such as polycystic ovary syndrome.</li><li>Oestrogens lead to elevated SHBG levels, whereas testosterone levels may be only slightly changed; therefore, the FAI can be markedly improved by the combined oral contraceptive (COC). In view of this, the COC should be stopped for at least 2 months before carrying out the test [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Blume-Peytavi et al, 2010</a>], which is not always practical.</li></ul></li><li><strong>Prolactin</strong><ul><li>Previous expert reviewers of this CKS topic were not unanimous on whether it is necessary to include prolactin as part of endocrine testing in primary care. This reflects a degree of uncertainty regarding the relationship between prolactin levels and alopecia. However, several reviewers thought that identifying a possible prolactinoma justified testing. </li></ul></li></ul></li></ul><h4>Seeking specialist advice or arranging endocrinology referral</h4><ul><li>Testing for FAI and prolactin may not always be practical or available in primary care. CKS recommends that if there is any uncertainty, specialist advice should be sought or referral to an endocrinologist arranged. </li><li>In women, elevated androgen levels may be due to polycystic ovary syndrome, but other causes should be considered, such as congenital adrenal hyperplasia, androgen-secreting tumours, and Cushing's syndrome. More detailed and specific testing can be guided by a specialist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Blume-Peytavi et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-female/references/\">Herskovitz et al, 2013</a>].</li></ul><!-- end field a1af8d59-cdd0-47ea-b75e-46ee5c308da6 --><!-- end item 81af5581-5a95-4e4f-9732-8f56d4f31a3b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}